Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) Gross Margin (2020 - 2025)

Bioventus (BVS) has disclosed Gross Margin for 6 consecutive years, with 68.89% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Margin rose 208.0% year-over-year to 68.89%, compared with a TTM value of 68.33% through Dec 2025, up 61.0%, and an annual FY2025 reading of 68.33%, up 61.0% over the prior year.
  • Gross Margin was 68.89% for Q4 2025 at Bioventus, up from 67.96% in the prior quarter.
  • Across five years, Gross Margin topped out at 72.83% in Q2 2021 and bottomed at 58.96% in Q4 2022.
  • Average Gross Margin over 5 years is 67.02%, with a median of 67.31% recorded in 2021.
  • The sharpest move saw Gross Margin tumbled -834bps in 2022, then skyrocketed 618bps in 2024.
  • Year by year, Gross Margin stood at 67.3% in 2021, then decreased by -12bps to 58.96% in 2022, then rose by 8bps to 63.73% in 2023, then increased by 5bps to 66.82% in 2024, then rose by 3bps to 68.89% in 2025.
  • Business Quant data shows Gross Margin for BVS at 68.89% in Q4 2025, 67.96% in Q3 2025, and 69.14% in Q2 2025.